EDAP TMS announced preliminary record Focal One System sales for the fourth quarter of calendar year 2024, reporting 11 Focal One Systems sold worldwide. This reflects robust demand for its Focal One Robotic HIFU technology.
The company also achieved record U.S. Focal One system sales during the fourth quarter. Furthermore, the number of U.S. Focal One procedures reached a record high, demonstrating a 30% year-over-year growth.
This strong preliminary performance underscores the increasing adoption of Focal One Robotic HIFU as a mainstream treatment option for prostate cancer. The company anticipates continued growth in its Focal One pipeline into 2025.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.